Metvix

Methyl aminolevulinate, the active ingredient in Metvix, is a photosensitizer presented as a 16% w/w cream for topical use. It is applied to skin lesions and, when activated by red light, selectively destroys abnormal keratinocytes, making it indicated for the treatment of actinic keratosis in adults with sun‑damaged skin.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing quality‑assured batches that meet EU regulatory standards and supporting customers with logistics, regulatory documentation and post‑supply technical assistance.

Metvix is used in photodynamic therapy for precancerous skin lesions. - Actinic keratosis: clears visible lesions and reduces the risk of progression to squamous cell carcinoma.

Metvix may cause a range of local and systemic reactions.

Common Side Effects: - Pain at the application site: discomfort during or after light activation. - Redness (erythema): visible skin flushing around treated area. - Swelling (edema): mild to moderate tissue edema. - Crusting: formation of a crust over the lesion. - Itching: pruritus in the treated zone. - Burning sensation: transient heat feeling.

Serious or Rare Side Effects: - Severe photosensitivity reaction: exaggerated skin response to light. - Infection of treated area: bacterial colonisation requiring medical attention. - Persistent ulceration: non‑healing sores beyond expected healing time. - Scarring: permanent tissue changes after lesion resolution. - Allergic contact dermatitis: immune‑mediated skin rash. - Rare systemic reactions: systemic hypersensitivity or anaphylaxis.

Before using Metvix, consider the following safety measures. - Lesion assessment: ensure lesions are suitable for photodynamic therapy. - Sun avoidance: protect treated skin from natural sunlight for at least 48 hours. - Protective dressings: cover the area after application to limit unintended light exposure. - Porphyria screening: avoid use in patients with known porphyria disorders. - Hypersensitivity check: discontinue if allergic reaction occurs. - Store at room temperature: keep in the original container, protect from light and moisture.

Metvix may interact with other agents that affect photosensitivity or skin healing.

Major Interactions (Avoid): - Systemic photosensitizers (e.g., tetracyclines, sulfonamides): increase risk of severe phototoxicity. - Oral retinoids: amplify skin irritation and photosensitivity.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may reduce therapeutic efficacy. - Other topical irritants (e.g., chemical peels): can exacerbate local skin reactions. - Anticoagulants: monitor for prolonged bleeding if ulceration occurs.